Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: wpckr who wrote (652)	5/15/1998 7:28:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

Biogen relies on Avonex, a recombinant beta interferon, for most of its revenues. Schering and Ares-Serono also make beta interferon. Serono is unlikely to get approval in the US because Avonex is protected under the orphan drug act, but they can now officially sell in Europe. However, both Schering and A-S's interferons are injected sub-cutaneously every other day(v. once per week), cause a much larger percentage (20% v. less than 5%) of patients to develop anti-bodies, and have not been shown to be as statistically effective as Avonex. In Europe, A-S will be a serious competitor. Biogen's European marketing effectiveness is unknown as of yet.